Gyre Therapeutics (GYRE) awards GC 50,000 options at $6.05
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
GYRE THERAPEUTICS, INC. reported a Form 4 showing that GC and Corporate Secretary Joshua Benjamin Bergmann received a grant of stock options to acquire 50,000 shares of common stock at an exercise price of $6.05 per share. These options expire on June 8, 2036. According to the vesting terms, 25% of the grant will vest on June 8, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to continued service. After this grant, Bergmann holds 50,000 derivative securities directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bergmann Joshua Benjamin
Role
GC and Corporate Secretary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 50,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 50,000 options
Exercise price: $6.05 per share
Expiration date: June 8, 2036
+3 more
6 metrics
Option grant size
50,000 options
Stock Option (Right to Buy) granted on June 8, 2026
Exercise price
$6.05 per share
Exercise price of granted stock options
Expiration date
June 8, 2036
Option expiration for 50,000-share grant
Initial vesting
25% vests June 8, 2027
First tranche of option vesting
Remaining vesting period
3 years monthly
Remaining options vest in equal monthly installments
Holdings after grant
50,000 derivative securities
Total options held directly following transaction
Key Terms
Stock Option (Right to Buy), vesting, exercise price, expiration date
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vesting financial
"25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: 6.0500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transaction did Gyre Therapeutics (GYRE) report for Joshua Benjamin Bergmann?
Gyre Therapeutics reported that GC and Corporate Secretary Joshua Benjamin Bergmann received a grant of stock options for 50,000 shares. The options are equity compensation, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.
How many Gyre Therapeutics (GYRE) options were granted to Joshua Benjamin Bergmann?
The Form 4 shows Bergmann was granted stock options covering 50,000 shares of Gyre Therapeutics common stock. This entire amount is a single option award and represents his total derivative position immediately after the reported transaction in the filing.
What is the exercise price and expiration date of the GYRE options granted to Bergmann?
The granted stock options have an exercise price of $6.05 per share and expire on June 8, 2036. This means Bergmann can choose to buy Gyre Therapeutics common shares at $6.05 any time before that expiration date, once vested.
How do the Gyre Therapeutics (GYRE) options granted to Bergmann vest over time?
The option grant vests 25% on June 8, 2027, with the remaining 75% vesting in equal monthly installments over the next three years. Vesting is contingent on Bergmann’s continued service to Gyre Therapeutics through each applicable vesting date.
What role does Joshua Benjamin Bergmann hold at Gyre Therapeutics (GYRE) in this Form 4?
The filing identifies Joshua Benjamin Bergmann as an officer of Gyre Therapeutics, serving as GC and Corporate Secretary. The reported stock option grant is part of his equity compensation in that officer capacity, subject to the vesting schedule described.